A systems approach for tumor pharmacokinetics

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Thurber, Greg Michael ^a   Weissleder, Ralph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CETUXIMAB; DOXORUBICIN; FLUORODEOXYGLUCOSE; OXYGEN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; EXTRAVASATION; HUMAN; HUMAN CELL; MACROMOLECULE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NONHUMAN; PHARMACOKINETICS; SYSTEMS BIOLOGY; TISSUE PERFUSION; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HT29 CELLS; HUMANS; MICE; MODELS, THEORETICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052841941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024696     Document Type: Article

References (67)

1. Minchinton AI, Tannock IF, (2006) Drug penetration in solid tumours. Nature Reviews Cancer 6: 583-592.
2. van der Greef J, McBurney RN, (2005) Innovation- Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nature Reviews Drug Discovery 4: 961-967.
3. Thurber GM, Weissleder R, (2010) Quantitating Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression Levels. Molecular Imaging and Biology.
4. Tolmachev V, Wallberg H, Sandstrom M, Hansson M, Wennborg A, et al. (2011) Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging.
5. Allerheiligen SRB, (2010) Next-Generation Model-Based Drug Discovery and Development: Quantitative and Systems Pharmacology. Clinical Pharmacology & Therapeutics 88: 135-137.
6. Breimer D, (2008) PK/PD Modelling and Beyond: Impact on Drug Development. Pharmaceutical Research 25: 2720-2722.
7. Jusko WJ, (1973) Pharmacodynamic Model for Cell-Cycle-Specific Chemotherapeutic Agents. Journal of Pharmacokinetics and Biopharmaceutics 1: 175-200.
8. Bischoff KB, Dedrick RL, Zaharko DS, Longstre JA, (1971) Methotrexate Pharmacokinetics. Journal of Pharmaceutical Sciences 60: 1128-&.
9. Heijn M, Roberge S, Jain RK, (1999) Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor. 59: 4458-4463.
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 350: 2335-2342.
11. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF, (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. Journal of Clinical Oncology 24: 823-834.
12. Goldman D, (2008) Theoretical Models of Microvascular Oxygen Transport to Tissue. Microcirculation 15: 795-811.
13. Dewhirst MW, Klitzman B, Braun RD, Brizel DM, Haroon ZA, et al. (2000) Review of methods used to study oxygen transport at the microcirculatory level. International Journal of Cancer 90: 237-255.
14. Pries AR, Hopfner M, le Noble F, Dewhirst MW, Secomb TW, (2010) The shunt problem: control of functional shunting in normal and tumour vasculature. Nature Reviews Cancer 10: 587-U589.
15. Secomb TW, Hsu R, Park EYH, Dewhirst MW, (2004) Green's function methods for analysis of oxygen delivery to tissue by microvascular networks. Annals of Biomedical Engineering 32: 1519-1529.
16. Torres IP, Leunig M, Yuan F, Intaglietta M, Jain RK, (1994) Noninvasive Measurement of Microvascular and Interstitial Oxygen Profiles in a Human Tumor in Scid Mice. 91: 2081-2085.
17. Eggleton CD, Vadapalli A, Roy TK, Popel AS, (2000) Calculations of intracapillary oxygen tension distributions in muscle. Mathematical Biosciences 167: 123-143.
18. Patlak CS, Blasberg RG, Fenstermacher JD, (1983) Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Journal of Cerebral Blood Flow and Metabolism 3: 1-7.
19. Castell F, Cook GJR, (2008) Quantitative techniques in (18)FDG PET scanning in oncology. British Journal of Cancer 98: 1597-1601.
20. Thurber GM, Schmidt MM, Wittrup KD, (2008) Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Advanced Drug Delivery Reviews 60: 1421-1434.
21. Jain RK, (1999) Transport of Molecules, Particles, and Cells in Solid Tumors. Annual Reviews in Biomedical Engineering 01: 241-263.
22. Hinderling PH, (1997) Red blood cells: A neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacological Reviews 49: 279-295.
23. Jain RK, Baxter L, (1988) Mechanisms of Heterogeneous Distribution of Monoclonal Antibodies and Other Macromolecules in Tumors: Significance of Elevated Interstitial Pressure. Cancer Research 48: 7022-7032.
24. Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, et al. (2008) Tumor blood flow measured by PET dynamic imaging of first-pass F-18-FDG uptake: A comparison with O-15-Labeled water-measured blood flow. Journal of Nuclear Medicine 49: 517-523.
25. Vaupel P, Kallinowski F, Okunieff P, (1989) Blood-flow, oxygen and nutrient supply, and metabolic microenvironment of human-tumors- a review. Cancer Research 49: 6449-6465.
26. Gerlowski L, Jain RK, (1986) Microvascular Permeability of Normal and Neoplastic Tissues. Microvascular Research 31: 288-305.
27. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, et al. (2001) Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proceedings of the National Academy of Sciences of the United States of America 98: 4628-4633.
28. Tzafriri AR, Levin AD, Edelman ER, (2009) Diffusion-limited binding explains binary dose response for local arterial and tumour drug delivery. Cell Proliferation 42: 348-363.
29. Sutherland R, (1988) Cell and Environment Interactions in Tumor Microregions: The Multicell Spheroid Model. Science 240: 177-184.
30. Tannock I, Lee C, Tunggal J, Cowan D, Egorin M, (2002) Limited Penetration of Anticancer Drugs through Tumor Tissue: A Potential Cause of Resistance of Solid Tumors to Chemotherapy. Clinical Cancer Research 8: 878-884.
31. Gounaris E, Tung CH, Restaino C, Maehr R, Kohler R, et al. (2008) Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS ONE 3: e2916.
32. Mattes MJ, Griffiths G, Diril H, Goldenberg D, Ong G, et al. (1994) Processing of Antibody-Radioisotope Conjugates after Binding to the Surface of Tumor Cells. Cancer 73: 787-793.
33. Smith TAD, (2001) The rate-limiting step for tumor [F-18]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nuclear Medicine and Biology 28: 1-4.
34. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD, (1999) Glut-1 and hexokinase expression: Relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Research 59: 4709-4714.
35. Thurber G, Figueiredo J, Weissleder R, (2009) Multicolor Fluorescent Intravital Live Microscopy (FILM) for Surgical Tumor Resection in a Mouse Xenograft Model. PLoS ONE 4: e8053.
36. Chaplin DJ, Olive PL, Durand RE, (1987) Intermittent Blood-Flow in a Murine Tumor- Radiobiological Effects. Cancer Research 47: 597-601.
37. Wang CY, Bassingthwaitghte JB, (2001) Capillary supply regions. Mathematical Biosciences 173: 103-114.
38. Thurber GM, Zajic SC, Wittrup KD, (2007) Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48: 995-999.
39. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, et al. (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Japanese Journal of Cancer Research 89: 307-314.
40. Schmidt MM, Wittrup KD, (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Molecular Cancer Therapeutics 8: 2861.
41. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, et al. (2005) Dependence of FDG uptake on tumor microenvironment. International Journal of Radiation Oncology Biology Physics 62: 545-553.
42. Thurber GM, Wittrup KD, (2008) Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Research 68: 3334-3341.
43. Flynn A, Boxer G, Begent R, Pedley R, (2001) Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunology and immunotherapy 50: 77-81.
44. Deen W, (1998) Analysis of Transport Phenomena:Oxford University Press.
45. Middleman S, (1972) Transport Phenomena in the Cardiovascular System. New York Wiley-Interscience.
46. Patton JN, Palmer AF, (2006) Numerical simulation of oxygen delivery to muscle tissue in the presence of hemoglobin-based oxygen carriers. Biotechnology Progress 22: 1025-1049.
47. Fujimori K, Covell DG, Fletcher JE, Weinstein JN, (1990) A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 31: 1191-1198.
48. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, et al. (2009) Associations between the uptake of In-111-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. European Journal of Nuclear Medicine and Molecular Imaging 36: 81-93.
49. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T-1-weighted MRI of a diffusable tracer: Standardized quantities and symbols. Journal of Magnetic Resonance Imaging 10: 223-232.
50. Wu AM, Senter PD, (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology 23: 1137-1146.
51. Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, et al. (2008) Metastatic human colonic carcinoma: Molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology 246: 497-507.
52. Yao ZS, Zhang ML, Garmestani K, Axworthy DB, Mallett RW, et al. (2004) Pretargeted alpha emitting radioimmunotherapy using Bi-213 1,4,7,10-tetraazacyclododecane-N,N ′,N ″,N ‴-tetraacetic acid-biotin. Clinical Cancer Research 10: 3137-3146.
53. Jain RK, (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62.
54. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, et al. (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-II. British Journal of Cancer 88: 1979-1986.
55. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, et al. (2009) Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. New England Journal of Medicine 360: 563-572.
56. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, et al. (2009) A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. Journal of Clinical Oncology 27: 672-680.
57. Levitt DG, (2010) Quantitative relationship between the octanol/water partition coefficient and the diffusion limitation of the exchange between adipose and blood. BMC Clin Pharmacol 10: 1.
58. Pruijn FB, Patel K, Hay MP, Wilson WR, Hicks KO, (2008) Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters. Australian Journal of Chemistry 61: 687-693.
59. Schroeder T, Yuan H, Viglianti BL, Peltz C, Asopa S, et al. (2005) Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Research 65: 5163-5171.
60. Baxter LT, Jain RK, (1990) Transport of Fluid and Macromolecules in Tumors: 2. Role of Heterogeneous Perfusion and Lymphatics. Microvascular Research 40: 246-263.
61. Baish JW, Gazit Y, Berk DA, Nozue M, Baxter LT, et al. (1996) Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res 51: 327-346.
62. Frykholm G, Glimelius B, Richter S, Carlsson J, (1991) Heterogeneity in Antigenic Expression and Radiosensitivity in Human Colon-Carcinoma Cell-Lines. In Vitro Cellular & Developmental Biology 27: 900-906.
63. Fujimori K, Covell D, Fletcher J, Weinstein J, (1989) Modeling Analysis of the Global and Microscopic Distribution of Immunoglobulin G, F(ab')2, and Fab in Tumors. Cancer Research 49: 5656-5663.
64. Baxter L, Zhu H, Mackensen D, Jain RK, (1994) Physiologically Based Pharmacokinetic Model for Specific and Nonspecific Monoclonal Antibodies and Fragments in Normal Tissues and Human Tumor Xenografts in Nude Mice. Cancer Research 54: 1517-1528.
65. Poulin P, Theil FP, (2002) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. Journal of Pharmaceutical Sciences 91: 1358-1370.
66. Ferl GZ, Kenanova V, Wu AM, DiStefano JJ, (2006) A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. 5: 1550-1558.
67. Garg A, Balthasar JP, (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Journal of Pharmacokinetics and Pharmacodynamics 34: 687-709.